Ashley F. Haggerty

Oncology

1610 Route 88
Suite 203
Brick, NJ 8724.

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 74 publications

A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.

A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.

Journal: Gynecologic oncology

Published: May 12, 2025

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.

Journal: Journal of comparative effectiveness research

Published: December 06, 2024

Prior authorization for FDA-approved PARP inhibitors in ovarian cancer.

Prior authorization for FDA-approved PARP inhibitors in ovarian cancer.

Journal: Gynecologic oncology reports

Published: January 23, 2024

"Having cancer is very expensive": A qualitative study of patients with ovarian cancer and PARP inhibitor treatment.

"Having cancer is very expensive": A qualitative study of patients with ovarian cancer and PARP inhibitor treatment.

Journal: Gynecologic oncology

Published: January 10, 2024

Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).

Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 31, 2023

Extended Venous Thromboembolism Prophylaxis after Robotic Staging for Endometrial Cancer.

Extended Venous Thromboembolism Prophylaxis after Robotic Staging for Endometrial Cancer.

Journal: Southern medical journal

Published: October 03, 2023

Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue.

Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue.

Journal: Gynecologic oncology

Published: August 04, 2023

Electronic medical record documentation of germline genetic evaluations in patients with ovarian cancer.

Electronic medical record documentation of germline genetic evaluations in patients with ovarian cancer.

Journal: Journal of genetic counseling

Published: February 14, 2023

Insurance status and time to radiation care after pathologic diagnosis for cervical cancer patients.

Insurance status and time to radiation care after pathologic diagnosis for cervical cancer patients.

Journal: Gynecologic oncology reports

Published: February 13, 2023

Insurance and racial disparities in prior authorization in gynecologic oncology.

Insurance and racial disparities in prior authorization in gynecologic oncology.

Journal: Gynecologic oncology reports

Published: January 09, 2023

Addition of External Beam Radiation Therapy to Adjuvant Chemotherapy for Patients With Stage IIIC Uterine Endometrioid Carcinoma: Utilization and Outcomes.

Addition of External Beam Radiation Therapy to Adjuvant Chemotherapy for Patients With Stage IIIC Uterine Endometrioid Carcinoma: Utilization and Outcomes.

Journal: American journal of clinical oncology

Published: August 04, 2022

Safety of ovarian preservation for premenopausal patients with FIGO stage I grade 2 and 3 endometrioid endometrial adenocarcinoma.

Safety of ovarian preservation for premenopausal patients with FIGO stage I grade 2 and 3 endometrioid endometrial adenocarcinoma.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: July 26, 2022

Showing 1-12 of 74

Last Updated: 09/26/2026